Effect of pioglitazone on menstrual cyclicity

Effect of pioglitazone on menstrual cyclicity in young non obese women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201101012575N2

Enrollment

Registered

2011-01-13

Start date

2011-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poly Cystic Ovary Syndrome. Disorders of other endocrine glands

Interventions

Pioglitazone, 30 mg Tablet, once daily for 6 months.

Treatment - Drugs

Pioglitazone, 30 mg Tablet, once daily for 6 months

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: presence of PCOS, BMI=18.5-24.99 Exclusion criteria: History of drug consumption during last 3 months, Thyroid abnormalities, Adrenal Hyperplasia, Cushing's syndrome, Hyperprolactinemia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Menstrual period. Timepoint: Baseline and 6 months after intervention. Method of measurement: observation.	—

Secondary

Measure	Time frame
Weight. Timepoint: Before and after the intervention. Method of measurement: in kg.;BMI. Timepoint: Before and after the intervention. Method of measurement: Weight/Height*Height.;Blood LH. Timepoint: Before and after the intervention. Method of measurement: measurements of hormonal serum level.;Blood Testostrone. Timepoint: Before and after the intervention. Method of measurement: measurement of serum hormonal level.;Fasting Blood Insulin. Timepoint: Before and after the intervention. Method of measurement: fasting blood insuline.;Blood Cholestrol. Timepoint: Before and after the intervention. Method of measurement: serum level of cholestrol.;Triglycerid. Timepoint: Before and after the intervention. Method of measurement: serum level of TG.	—

Measure

Time frame

Weight. Timepoint: Before and after the intervention. Method of measurement: in kg.;BMI. Timepoint: Before and after the intervention. Method of measurement: Weight/Height*Height.;Blood LH. Timepoint: Before and after the intervention. Method of measurement: measurements of hormonal serum level.;Blood Testostrone. Timepoint: Before and after the intervention. Method of measurement: measurement of serum hormonal level.;Fasting Blood Insulin. Timepoint: Before and after the intervention. Method of measurement: fasting blood insuline.;Blood Cholestrol. Timepoint: Before and after the intervention. Method of measurement: serum level of cholestrol.;Triglycerid. Timepoint: Before and after the intervention. Method of measurement: serum level of TG.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Razieh Dehghani Firouzabadi

Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences

Dr_firouzabadi@ssu.ac.ir+98 35 1824 7085

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026